Traditional Chinese medicine combined with chemotherapy for breast cancer after operation: A systematic review and meta-analysis.

IF 1.3 4区医学 Q2 MEDICINE, GENERAL & INTERNAL Medicine Pub Date : 2024-11-15 DOI:10.1097/MD.0000000000040264

Yanran Zhang, Lihui Shi

{"title":"Traditional Chinese medicine combined with chemotherapy for breast cancer after operation: A systematic review and meta-analysis.","authors":"Yanran Zhang, Lihui Shi","doi":"10.1097/MD.0000000000040264","DOIUrl":null,"url":null,"abstract":"Background: This systematic review aims to explore the effect of traditional Chinese medicine combined with chemotherapy on the clinical efficacy of breast cancer postoperative patients, providing theoretical basis for the treatment of breast cancer postoperative patients with traditional Chinese medicine.Methods: A comprehensive search was conducted on databases such as China National Knowledge Infrastructure, Wanfang Database, VIP Database, Chinese Biomedical Literature Database, PubMed, and the Cochrane Library from their inception to August 2023 to screen RCTs comparing the effect of traditional Chinese medicine combined with chemotherapy with that of chemotherapy alone on the clinical efficacy of breast cancer postoperative patients. The included literature was systematically reviewed.Results: A total of 22 RCTs involving 1834 breast cancer postoperative patients were finally included, with 918 patients in the traditional Chinese medicine combined with chemotherapy group (treatment group) and 916 patients in the chemotherapy alone group (control group). Meta-analysis showed that compared with the control group, therapeutical effective rate, CD3, CD4, CD4/CD8, and adverse reactions in the treatment group were all improved, and the incidence of leukopenia and thrombocytopenia after chemotherapy were all reduced, with statistically significant differences.Conclusion: Traditional Chinese medicine combined with chemotherapy is superior to chemotherapy alone in improving the therapeutical effective rate after breast cancer surgery, reducing chemotherapy adverse reactions, and enhancing immune function.","PeriodicalId":18549,"journal":{"name":"Medicine","volume":"103 46","pages":"e40264"},"PeriodicalIF":1.3000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11575946/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MD.0000000000040264","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This systematic review aims to explore the effect of traditional Chinese medicine combined with chemotherapy on the clinical efficacy of breast cancer postoperative patients, providing theoretical basis for the treatment of breast cancer postoperative patients with traditional Chinese medicine.

Methods: A comprehensive search was conducted on databases such as China National Knowledge Infrastructure, Wanfang Database, VIP Database, Chinese Biomedical Literature Database, PubMed, and the Cochrane Library from their inception to August 2023 to screen RCTs comparing the effect of traditional Chinese medicine combined with chemotherapy with that of chemotherapy alone on the clinical efficacy of breast cancer postoperative patients. The included literature was systematically reviewed.

Results: A total of 22 RCTs involving 1834 breast cancer postoperative patients were finally included, with 918 patients in the traditional Chinese medicine combined with chemotherapy group (treatment group) and 916 patients in the chemotherapy alone group (control group). Meta-analysis showed that compared with the control group, therapeutical effective rate, CD3, CD4, CD4/CD8, and adverse reactions in the treatment group were all improved, and the incidence of leukopenia and thrombocytopenia after chemotherapy were all reduced, with statistically significant differences.

Conclusion: Traditional Chinese medicine combined with chemotherapy is superior to chemotherapy alone in improving the therapeutical effective rate after breast cancer surgery, reducing chemotherapy adverse reactions, and enhancing immune function.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

乳腺癌术后中医药联合化疗：系统综述和荟萃分析。

背景：本系统综述旨在探讨中医药联合化疗对乳腺癌术后患者临床疗效的影响，为中医药治疗乳腺癌术后患者提供理论依据：方法：在中国知网、万方数据库、VIP数据库、中国生物医学文献数据库、PubMed、Cochrane图书馆等数据库中进行全面检索，筛选中药联合化疗与单纯化疗对乳腺癌术后患者临床疗效的比较研究。对纳入的文献进行了系统回顾：最终共纳入 22 项研究，涉及 1834 例乳腺癌术后患者，其中中药联合化疗组（治疗组）918 例，单纯化疗组（对照组）916 例。荟萃分析显示，与对照组相比，治疗组的治疗有效率、CD3、CD4、CD4/CD8、不良反应均有所改善，化疗后白细胞减少症、血小板减少症的发生率均有所降低，差异有统计学意义：结论：中药联合化疗在提高乳腺癌术后治疗有效率、减少化疗不良反应、增强免疫功能方面优于单纯化疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Medicine 医学-医学：内科

CiteScore

2.80

自引率

0.00%

发文量

4342

审稿时长

>12 weeks

期刊介绍： Medicine is now a fully open access journal, providing authors with a distinctive new service offering continuous publication of original research across a broad spectrum of medical scientific disciplines and sub-specialties. As an open access title, Medicine will continue to provide authors with an established, trusted platform for the publication of their work. To ensure the ongoing quality of Medicine’s content, the peer-review process will only accept content that is scientifically, technically and ethically sound, and in compliance with standard reporting guidelines.